All In Biotech

Free tool

FAERS Monitor: Curosurf

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 020744 or its brand name (Curosurf, Poractant Alfa). Reports on generic versions are filed under their own applications.

Reports

737

Serious

685

93% of reports

Hospitalization

100

Death reported

222

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neonatal hypoxia121
  • off label use84
  • pulmonary haemorrhage78
  • bradycardia neonatal51
  • ill-defined disorder50
  • drug ineffective46
  • product complaint40
  • endotracheal intubation complication39
  • pneumothorax37
  • infantile apnoea30
  • neonatal respiratory failure28
  • pulmonary haemorrhage neonatal28
  • product quality issue27
  • product administration error26
  • cyanosis neonatal24

Reports by year received

View as table
YearReports
20045
20054
200616
200716
200812
20098
20109
20114
201213
201316
201411
201515
201618
201731
2018145
201968
2020109
202141
202254
202342
202456
202516
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pulmonary haemorrhage neonatalSignal2812497.88063.6234,781
neonatal hypoxiaSignal1214895.94094.2501,375
endotracheal intubation complicationSignal392021.91473.271,697
neonatal respiratory failureSignal281673.31151.042,643
bradycardia neonatalSignal511207.0920.757,817
cyanosis neonatalSignal241111.2743.824,567
infantile apnoeaSignal301090.3762.730,410
pulmonary haemorrhageSignal78287.4232.721,762
pneumothoraxSignal3766.848.72,328
product complaintSignal4045.133.41,681
product administration errorSignal2636.825.2869
ill-defined disorderSignal5023.518.01,057
product quality issueSignal275.73.9100
off label useSignal842.72.295
drug ineffective461.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.